Eli Lilly Exec Expects Obesity Pill Data in April 2025

Eli Lilly is set to release data from its late-stage trial of the experimental obesity pill, orforglipron, in April 2025. The drug belongs to a class that mimics the GLP-1 hormone, helping to regulate blood sugar, slow stomach emptying, and reduce appetite. Reports, such as the one from Medical Dialogues on June 11, 2024, emphasize that orforglipron is being developed for obesity management while also being explored for potential uses in Alzheimer's treatment.

Despite the interest in its broader applications, Lilly Diabetes and Obesity President Patrik Jonsson remains skeptical about the pill’s direct impact on Alzheimer’s. Instead, he highlighted that the drug might more effectively target underlying conditions like obesity and stroke, both of which could contribute to cognitive decline. This nuanced outlook underscores the rigorous assessment of orforglipron's benefits as clinical data is expected to emerge next year.